Format

Send to

Choose Destination
Microbes Infect. 2005 May;7(5-6):922-31. Epub 2005 Apr 14.

Tuberculosis vaccine development; from mouse to man.

Author information

1
Infectious Disease Research Institute, 1124 Columbia St, Ste 600, Seattle, WA 98104, USA. sreed@idri.org

Abstract

A tuberculosis (TB) vaccine candidate, Mtb72, was developed following an antigen discovery program involving a combination of expression cloning strategies and evaluation of human immune responses. Adjuvant selection was also performed, resulting in the prioritization of AS02A and AS01B, and an industrial process for vaccine production was developed. Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A.

PMID:
15935717
DOI:
10.1016/j.micinf.2005.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center